Medical Instrument Stocks
Recent market-moving SEC filings and news across medical instrument companies, ranked by Wiseek's 1–10 importance score.
How Wiseek curates this list
Every item here is a high-importance (score ≥ 7) SEC filing or licensed news event for a medical instrument company, sourced from SEC EDGAR and licensed news wires and ranked by Wiseek's 1–10 importance score. The underlying source is linked from each article. See our methodology and editorial policy.
Related Healthcare industries
Biotech StocksMedical Device StocksPharmaceutical StocksHealth Tech StocksDiagnostics & Research StocksHealthcare Facility Stocks
See the full Healthcare sector feed.
NEXGEL Ousts CEO, Launches Strategic Review Amid Going Concern Crisis
NexGel Registers 15.25M Shares for Resale, Allocating All Available Authorized Shares to Note Conversions
FDA Approves Modular PMA Pathway for FemBloc, Clearing Key Hurdle
Glucotrack Shareholders Approve Reverse Split and Warrant Inducement
Baxter Names John Rogers as CFO, Filling Key Leadership Gap
Baxter Upsizes Debt Tender to $600M and Loosens Leverage Covenant
Haemonetics Signs Non-Exclusive Supply Agreement with CSL Plasma for NexSys PCS Devices
ResMed Swaps Auditors from KPMG to PwC and Names Carol Burt Lead Director
Axe Compute Secures 55 MW AI Data Center Capacity in $500M+ Deal with Duos Technologies
Axe Compute and Duos Technologies Sign $500M+ Deal for 55 MW of AI Data Center Capacity
NexGel Q2 Revenue $3.69M, Net Loss $2.87M; Resolicits Shareholder Approval for Reverse Split
NEXGEL Q2 Revenue Misses as BioNX Integration Slows, Loss Widens to $2.87M
Nasdaq Grants Continued Listing as Glucotrack Regains Equity Compliance
NexGel Q2 10-Q: Going Concern, Potential Note Defaults, and Material Weaknesses
NexGel Seeks Shareholder Approval for Reverse Split and Up to 150M Authorized Shares
Axe Compute Q2 Revenue Surges to $3.2M, But Digital Asset Losses Drive $17.2M Net Loss
Axe Compute Posts $3.2M Revenue, $2.8B in New Contracts, $60.8M Prepayments
Femasys Q2 2026: Sales Fall 18.9%, Net Loss Narrows to $4.47M; $30M Private Placement Closed
Femasys Q2 Sales Fall 19% to $332K; Cash at $1.4M Before $30M Placement
Glucotrack 10-Q: Going Concern, Material Weaknesses, and Nasdaq Delisting Risk
Femasys Q2 Sales Fall 19%, Net Loss Narrows; $30M Placement Funds FemBloc Push
Innovative Eyewear Q2 Revenue Jumps 74% but Material Weakness in Controls Disclosed
Record Q2: Revenue Tops $1M, Gross Margin Swings to 24%
Zentek Reports Q1 FY2027 Loss, Going Concern Warning, and Albany Graphite PEA
ResMed FY2026 10-K: Full-Year Revenue Up 10%, MatrixCare Sale for $490M, Astral Recall Costs $42M
FDA Flags Medline Kits Over Contaminated BD Applicators
STAAR Surgical Q2 Sales Hit $93.5M, Swings to Profit on China Surge
STAAR Surgical Q2 2026: Net Income $8.1M, China Sales Surge 888%
UTMD Q2 2026: Revenue Down 14%, Litigation Costs Rise, Guidance Cut
Femasys Secures First Blended Polymer Patents for FemBloc, Expanding Global IP Protection
Bausch + Lomb Appoints New Chairman and Lead Independent Director
L1 Capital Extends Distribution Streak with Another $5.8M Sale of Anteris Technologies
CEO Kathy Lee-Sepsick puts $50K of her own money into Femasys's $3.20/share private placement
Anteris Posts 30c Q2 Loss as Trial Costs Widen
Sanara MedTech Q2 Revenue Misses, Swings to Loss; MiMedx Merger Looms
Femasys Closes $30M Private Placement, Grants Board Seats to Lead Investor Alongside Heavy Warrant Issuance
Harvard Bioscience Lifts Full-Year Outlook as Q2 Revenue Climbs 11%
Sanara MedTech Q2 Revenue Misses Estimates, Posts Net Loss Amid Acquisition Costs
Sanara MedTech Q2 Revenue Misses, Swings to Loss Amid Pending MiMedx Acquisition
Anteris Q2 2026: $260.9M Cash Cushion, but Losses Deepen as PARADIGM Trial Costs Surge; Material Weaknesses Linger